Abstract
Angiotensin-converting enzyme is used as a marker for sarcoid activity. We describe a case of remission of cutaneous and lymphatic sarcoidosis in a patient treated with an ACE inhibitor for congestive heart failure and hypertension; the remission has continued over 4 years of follow-up. Because this is a report of only one case, there is a possibility of sampling error. Whether the patient’s remission in this case was a serendipitous spontaneous remission that happened to occur during ACE inhibitor therapy or whether ACE inhibitor therapy can play a role in the treatment of sarcoidosis needs to be determined in a large clinical trial.
Similar content being viewed by others
References
Leiberman J. Evaluation of serum angiotensin converting enzyme levels in sarcoidosis. Am J Med 1975; 59: 365–72
Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis: its value in present clinical practice. Ann Clin Biochem 1989; 26: 13–8
Silverstein E, Friedland J, Pertschuk LP. Sarcoidosis pathogenesis: mechanisms of angiotensin converting enzyme elevation: epithelioid cell localization and induction in macrophages and monocytes in culture. In: Jones-Williams W, Davies BH, editors. Proceedings of 8th International Conference on sarcoidosis and other granulomatous diseases. Cardiff: Alpha and Omega Press, 1980: 246
Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis: detection of angiotensin converting enzyme in sarcoid granulomas. Am J Clin Pathol 1981; 75: 350–4
Scadding JG, Mitchell DN. Sarcoidosis. London: Chapman & Hall Medical, 1985: 181–206
Vien NK, Stahl D, Brodthagen H. Cutaneous sarcoidosis in Caucasians [abstract]. J Am Acad Dermatol 1987; 16: 534
Mizuno K, Okamoto H, Horio T. Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors. Br J Dermatol 2004; 150: 205–10
Anthony F, Layton AMA. Case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 2000; 142: 1052–3
Claridge MW, Hobbs SD, Quick C. ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitor. Eur J Vasc Endovasc Surg 2004; 28: 67–70
Pfeffer MA, Pfeffer JM, Steinberg C. Survival after an experimental myocardial infarction: beneficial effects of long term therapy with captopril. Circulation 1985; 72: 406–12
Parmothayan S, Jones PW. Steroid therapy of sarcoidosis. JAMA 2002 Mar 13; 287 (10): 1301–7
Jones E, Callen JP. Hydroxychoroquine is effective therapy for control of cutaneous sarcoidal granulomas [abstract]. J Am Acad Dermatol 1990; 23: 487–9
Webster GF, Razsi LK, Sanches M. Weekly low dose methotrexate therapy for cutaneous sarcoidosis [abstract]. J Am Acad Dermatol 1991; 24: 451–4
Carlesimo M, Giustini S, Rossi A. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866–9
Tseng S, Pak G, Washenik K. Rediscovering thalidomide: a review of its mechanism of action side effects and potential uses. J Am Acad Dermatol 1996; 35: 969–79
Cagnoni ML, Lombardi A, Cerinic MM. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 346 (8984): 1229–30
Yamada H, Ide A, Sugiura M. Treatment of cutaneous sarcoidosis with tranilast. J Dermatol 1995; 22 (2): 149–52
Acknowledgments
No sources of funding were used to assist in the preparation of this case report. The authors have no conflicts of interest that are directly relevant to the content of this case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaura, V., Kaura, S.H. & Kaura, C.S. ACE Inhibitor in the Treatment of Cutaneous and Lymphatic Sarcoidosis. AM J Clin Dermatol 8, 183–186 (2007). https://doi.org/10.2165/00128071-200708030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200708030-00006